Jedd D. Wolchok

204.8k total citations · 48 hit papers
568 papers, 65.0k citations indexed

About

Jedd D. Wolchok is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jedd D. Wolchok has authored 568 papers receiving a total of 65.0k indexed citations (citations by other indexed papers that have themselves been cited), including 431 papers in Oncology, 315 papers in Immunology and 162 papers in Molecular Biology. Recurrent topics in Jedd D. Wolchok's work include Cancer Immunotherapy and Biomarkers (323 papers), Immunotherapy and Immune Responses (250 papers) and CAR-T cell therapy research (232 papers). Jedd D. Wolchok is often cited by papers focused on Cancer Immunotherapy and Biomarkers (323 papers), Immunotherapy and Immune Responses (250 papers) and CAR-T cell therapy research (232 papers). Jedd D. Wolchok collaborates with scholars based in United States, France and Italy. Jedd D. Wolchok's co-authors include Antoni Ribas, Margaret K. Callahan, F. Stephen Hodi, Michael A. Postow, Taha Merghoub, James P. Allison, Michael A. Postow, Jeffrey S. Weber, Andrew M. Scott and Weiping Zou and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jedd D. Wolchok

547 papers receiving 63.9k citations

Hit Papers

Cancer immunotherapy using checkpoint bl... 2009 2026 2014 2020 2018 2009 2015 2016 2012 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer immunotherapy using checkpoint blockade
    2018 4.6k citations Jedd D. Wolchok et al. profile →
  2. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
    2009 2.3k citations Jedd D. Wolchok, Steven O’Day et al. Clinical Cancer Research profile →
  3. Immune Checkpoint Blockade in Cancer Therapy
    2015 2.1k citations Margaret K. Callahan, Jedd D. Wolchok et al. Journal of Clinical Oncology profile →
  4. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
    2016 1.9k citations Jedd D. Wolchok et al. profile →
  5. Antibody therapy of cancer
    2012 1.7k citations Jedd D. Wolchok et al. profile →
  6. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    2015 1.6k citations Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  7. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
    2017 1.5k citations F. Stephen Hodi, Jedd D. Wolchok et al. profile →
  8. RECIST 1.1—Update and clarification: From the RECIST committee
    2016 1.2k citations F. Stephen Hodi, Jedd D. Wolchok et al. profile →
  9. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    2015 1.2k citations Mario E. Lacouture, Michael A. Postow et al. profile →
  10. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
    2013 1.1k citations Jedd D. Wolchok, James P. Allison et al. The Journal of Experimental Medicine profile →
  11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. profile →
  12. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    2009 934 citations Jedd D. Wolchok, Jose Lutzky et al. profile →
  13. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
    2016 924 citations Jedd D. Wolchok et al. profile →
  14. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
    2017 874 citations Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  15. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    2012 826 citations Omid Hamid, Donald P. Lawrence et al. profile →
  16. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
    2015 808 citations Parisa Momtaz, Michael A. Postow et al. Journal of Clinical Oncology profile →
  17. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
    2016 773 citations Margaret K. Callahan, Eric G. Pamer et al. profile →
  18. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    2019 638 citations Omid Hamid, F. Stephen Hodi et al. profile →
  19. Chromatin states define tumour-specific T cell dysfunction and reprogramming
    2017 605 citations Taha Merghoub, Matthew D. Hellmann et al. profile →
  20. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
    2014 564 citations Taha Merghoub, Jedd D. Wolchok et al. profile →
  21. Clinical implications of T cell exhaustion for cancer immunotherapy
    2022 559 citations Jedd D. Wolchok et al. profile →
  22. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
    2021 557 citations Jedd D. Wolchok, Taha Merghoub et al. profile →
  23. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
    2014 537 citations Margaret K. Callahan, Jedd D. Wolchok et al. profile →
  24. The future of cancer immunotherapy: microenvironment-targeting combinations
    2020 535 citations Allison Betof Warner, Jedd D. Wolchok et al. profile →
  25. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
    2013 522 citations Jedd D. Wolchok, James P. Allison et al. The Journal of Experimental Medicine profile →
  26. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
    2017 511 citations Jedd D. Wolchok et al. profile →
  27. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
    2011 504 citations David Schaer, Jedd D. Wolchok et al. profile →
  28. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    2011 492 citations Padmanee Sharma, Jedd D. Wolchok et al. profile →
  29. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    2016 486 citations Jedd D. Wolchok, Taha Merghoub et al. profile →
  30. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
    2020 477 citations Roberta Zappasodi, Jedd D. Wolchok et al. profile →
  31. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
    2016 452 citations Jedd D. Wolchok, F. Stephen Hodi et al. profile →
  32. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
    2017 445 citations Matthew D. Hellmann, Taha Merghoub et al. profile →
  33. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    2018 418 citations Roberta Zappasodi, Taha Merghoub et al. profile →
  34. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
    2012 410 citations Christine A. Pratilas, Margaret K. Callahan et al. profile →
  35. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    2011 410 citations Charlotte E. Ariyan, Cristina R. Antonescu et al. profile →
  36. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
    2019 409 citations F. Stephen Hodi, Jedd D. Wolchok et al. profile →
  37. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
    2018 408 citations Anita Giobbie‐Hurder, Jeffrey S. Weber et al. profile →
  38. Immune Modulation in Cancer with Antibodies
    2013 403 citations Margaret K. Callahan, James P. Allison et al. profile →
  39. The hallmarks of successful anticancer immunotherapy
    2018 399 citations Jedd D. Wolchok et al. profile →
  40. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
    2018 374 citations Alexandra Snyder, David B. Solit et al. Journal of Clinical Oncology profile →
  41. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
    2015 371 citations Yanyun Li, James P. Allison et al. profile →
  42. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
    2010 358 citations Bradley Curtis Carthon, Jedd D. Wolchok et al. Clinical Cancer Research profile →
  43. Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
    2010 344 citations Geoffrey Y. Ku, Jianda Yuan et al. profile →
  44. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
    2020 335 citations Sadna Budhu, Cailian Liu et al. profile →
  45. Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
    2015 306 citations Jedd D. Wolchok, Christopher A. Barker et al. profile →
  46. Monoclonal Antibodies for Cancer Therapy
    2012 298 citations James P. Allison, Jedd D. Wolchok et al. profile →
  47. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    2011 254 citations Jianda Yuan, Matthew Adamow et al. profile →
  48. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    2013 233 citations Jedd D. Wolchok, F. Stephen Hodi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jedd D. Wolchok United States 119 45.3k 29.7k 16.2k 11.0k 4.6k 568 65.0k
Drew M. Pardoll United States 132 45.0k 1.0× 46.7k 1.6× 23.5k 1.5× 8.8k 0.8× 6.7k 1.5× 403 83.2k
Suzanne L. Topalian United States 82 32.6k 0.7× 27.0k 0.9× 12.4k 0.8× 7.7k 0.7× 4.0k 0.9× 215 49.2k
Antoni Ribas United States 110 39.7k 0.9× 22.6k 0.8× 27.4k 1.7× 7.5k 0.7× 6.3k 1.4× 551 61.0k
Gordon J. Freeman United States 141 38.6k 0.9× 54.1k 1.8× 14.7k 0.9× 8.3k 0.8× 5.2k 1.1× 419 82.7k
Mark J. Smyth Australia 143 37.6k 0.8× 52.9k 1.8× 20.2k 1.2× 5.1k 0.5× 6.5k 1.4× 595 81.6k
Lieping Chen United States 112 34.3k 0.8× 36.0k 1.2× 9.2k 0.6× 6.6k 0.6× 3.4k 0.7× 368 55.6k
Lisa M. Coussens United States 81 27.4k 0.6× 21.6k 0.7× 23.6k 1.5× 6.3k 0.6× 12.5k 2.7× 198 61.3k
F. Stephen Hodi United States 101 34.2k 0.8× 16.7k 0.6× 10.4k 0.6× 9.8k 0.9× 3.4k 0.7× 517 44.0k
Wolf H. Fridman France 100 27.6k 0.6× 31.2k 1.0× 16.6k 1.0× 8.5k 0.8× 7.0k 1.5× 529 57.4k
Seth M. Steinberg United States 124 29.1k 0.6× 12.8k 0.4× 15.6k 1.0× 13.6k 1.2× 7.9k 1.7× 864 58.9k

Countries citing papers authored by Jedd D. Wolchok

Since Specialization
Citations

This map shows the geographic impact of Jedd D. Wolchok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jedd D. Wolchok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jedd D. Wolchok more than expected).

Fields of papers citing papers by Jedd D. Wolchok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jedd D. Wolchok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jedd D. Wolchok. The network helps show where Jedd D. Wolchok may publish in the future.

Co-authorship network of co-authors of Jedd D. Wolchok

This figure shows the co-authorship network connecting the top 25 collaborators of Jedd D. Wolchok. A scholar is included among the top collaborators of Jedd D. Wolchok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jedd D. Wolchok. Jedd D. Wolchok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smithy, James W., Colleen Maher, Alexander N. Shoushtari, et al.. (2023). Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).. Journal of Clinical Oncology. 41(16_suppl). 9517–9517.
2.
Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.
3.
Wang, Weiyi, Peihong Dai, Ning Yang, et al.. (2021). Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. Journal for ImmunoTherapy of Cancer. 9(9). e002569–e002569. 16 indexed citations
4.
Martens, Alexander, Kilian Wistuba‐Hamprecht, Jianda Yuan, et al.. (2016). Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research. 22(19). 4848–4858. 141 indexed citations
5.
Brea, Elliott J., Claire Y. Oh, Eusebio Manchado, et al.. (2016). Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. 4(11). 936–947. 128 indexed citations
6.
Nathanson, Tavi, Arun Ahuja, Alex Rubinsteyn, et al.. (2016). Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research. 5(1). 84–91. 122 indexed citations
7.
Москаленко, Марина, Michael Pan, Yichun Fu, et al.. (2015). Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. Cancer Immunology Research. 3(3). 296–304. 19 indexed citations
8.
Carvajal, Richard D., Donald P. Lawrence, Jeffrey S. Weber, et al.. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research. 21(10). 2289–2296. 97 indexed citations
9.
Kitano, Shigehisa, Michael A. Postow, Carly G.K. Ziegler, et al.. (2014). Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. Cancer Immunology Research. 2(8). 812–821. 111 indexed citations
10.
Avogadri, Francesca, Roberta Zappasodi, Arvin Yang, et al.. (2014). Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. Cancer Immunology Research. 2(5). 448–458. 36 indexed citations
11.
Barker, Christopher A., Michael A. Postow, Shaheer Khan, et al.. (2013). Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma. Cancer Immunology Research. 1(2). 92–98. 127 indexed citations
12.
Callahan, Margaret K., Gregg Masters, Christine A. Pratilas, et al.. (2013). Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research. 2(1). 70–79. 91 indexed citations
13.
Schaer, David, Sadna Budhu, Cailian Liu, et al.. (2013). GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research. 1(5). 320–331. 121 indexed citations
14.
Catalanotti, Federica, David B. Solit, Melissa Pulitzer, et al.. (2013). Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research. 19(8). 2257–2264. 112 indexed citations
15.
Kitano, Shigehisa, Takemasa Tsuji, Daniel Hirschhorn-Cymerman, et al.. (2013). Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research. 1(4). 235–244. 96 indexed citations
16.
Hirschhorn-Cymerman, Daniel, Sadna Budhu, Shigehisa Kitano, et al.. (2012). Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of Experimental Medicine. 209(11). 2113–2126. 115 indexed citations
17.
Lesokhin, Alexander M., Tobias M. Hohl, Shigehisa Kitano, et al.. (2011). Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. Cancer Research. 72(4). 876–886. 292 indexed citations
18.
Patel, Mrinali, Elizabeth Smyth, Paul B. Chapman, et al.. (2011). Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma. Clinical Cancer Research. 17(8). 2087–2100. 83 indexed citations
19.
Carthon, Bradley Curtis, Jedd D. Wolchok, Jianda Yuan, et al.. (2010). Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research. 16(10). 2861–2871. 358 indexed citations breakdown →
20.
Duan, Fei, Yun Lin, Cailian Liu, et al.. (2009). Immune Rejection of Mouse Tumors Expressing Mutated Self. Cancer Research. 69(8). 3545–3553. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Suzanne L. Topalian Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Lisa M. Coussens Breakdown of academic impact, for papers by F. Stephen Hodi Breakdown of academic impact, for papers by Wolf H. Fridman Breakdown of academic impact, for papers by Seth M. Steinberg
Rankless by CCL
2026